key: cord-1048109-wtjaor60
authors: Pilla Reddy, Venkatesh; El‐Khateeb, Eman; Jo, Heeseung; Giovino, Natalie; Lythgoe, Emily; Sharma, Shringi; Tang, Weifeng; Jamei, Masoud; Rastomi‐Hodjegan, Amin
title: Pharmacokinetics under the COVID‐19 Storm
date: 2020-11-23
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14668
sha: 52a39c03c1ffd799cc921ff111e6a348377dc584
doc_id: 1048109
cord_uid: wtjaor60

AIMS: The storm‐like nature of the health crises caused by COVID‐19 has led to unconventional clinical trial practices such as the relaxation of exclusion criteria. The question remains: how can we conduct diverse trials without exposing sub‐groups of populations to potentially harmful drug exposure levels? The aim of this study was to build a knowledge‐base of the effect of intrinsic/extrinsic factors on the disposition of several repurposed COVID‐19 drugs. METHODS: PBPK models were used to study the change in PK of drugs repurposed for COVID‐19 in geriatric patients, different race groups, organ impairment, DDI risks. These models were also used to predict epithelial lining fluid (ELF) exposure which is relevant for COVID‐19 patients under elevated cytokine levels. RESULTS: The simulated PK profiles suggest no dose adjustments are required based on age and race for COVID‐19 drugs; however, dose adjustments may be warranted for COVID‐19 patients also exhibiting hepatic/renal impairment. PBPK model simulations suggest ELF exposure to attain a target concentration was adequate for most drugs, except for hydroxychloroquine, azithromycin, atazanavir and lopinavir/ritonavir. CONCLUSION: We demonstrate that systematically collated data on the ADME, human PK parameters, DDIs, and organ impairment can be used to verify simulated plasma and lung tissue exposure for drugs repurposed for COVID‐19, justifying broader patient recruitment criteria. In addition, the PBPK model developed was used to study the effect of age and ethnicity on the PK of repurposed drugs, and to assess the correlation between lung exposure and relevant potency values from in vitro studies for SARS‐CoV‐2.

INTRODUCTION "Necessity is the mother of invention": Desperate times have often led to unorthodox approaches to address an unmet need. s. Clinical trials in drug development are not an exception to this. In general, clinical trials are conducted in a systematic way and follow stringent recruitment criteria. Lack of diversity in patients recruited to drug trials was the subject of a recent draft Guidance for Industry by the US FDA, where they encouraged inclusion of the elderly, those at the extremes of the weight range, individuals with organ dysfunction, those with malignancies or certain infections such as HIV, and children [1] . This guidance emphasized the need to characterize drugs more comprehensively during early clinical development (e.g., with respect to drug metabolism and clearance pathways). In addition, the guidance indicated that dose adjustments can be made in specific populations to reduce significant differences in systemic exposure to the drug under investigation.

However, broadened recruitment of patients in COVID-19 drug trials has been an exception to the norm resulting from the speed of transmission of the virus. (Here we can put the reproduction rate from the next paragraph). The pandemic has accelerated adoption of the draft guidance on broadening recruitment. However, this risks exposing sub-groups of populations to higher drug levels , particularly for drugs that lack safety studies specific to these sub-groups.

COVID-19 pandemic in perspective: Several therapeutic agents have been evaluated for the treatment of COVID-19, but remdesivir, acalabrutinib, ibrutinib, and dexamethasone in particular have shown some positive results [2] [3] [4] . The FDA has issued guidance for COVID-19 trials [5] emphasising the need to consider participant safety alongside the need to establish the efficacy of drug against SARS-CoV-2. The estimated basic reproduction number for SARS-CoV-2 is 2.65 days (with a range from 1.85 to 3.41 days) [6] .

Drugs on Trial for COVID-19: As of May 21 st , 2020, there were 1,621 COVID-19 trials on clinicaltrials.gov, of which 912 are active and/or recruiting. To address the urgent need for therapeutic remedies for COVID-19, efforts to repurpose existing drugs are increasing hence most trials are focused on existing drugs rather than Investigational New Drugs. These repurposed drugs consist of anti-virals (azithromycin, atazanavir, baloxavir, darunavir, lopinavir, remdesivir, ritonavir), anti-cancer drugs (acalabrutinib, ibrutinib, baricitinib, ruxolitinib), anti-inflammatory (dexamethasone), large molecules (siltuximab, emapalumab, tocilizumab), antimalarials (chloroquine, hydroxychloroquine), and one anti-diabetic and heart failure treatment drug (dapagliflozin). Azithromycin is dosed in combination with hydroxychloroquine. [7] Typical COVID-19 Patient and Cytokine Storm: A typical hospitalized COVID-19 patient exhibits overproduction of early response pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6,), and interleukin-1 beta (IL-1β). This is known as a 'cytokine storm,'

and is thought to be one of the major causes of acute respiratory distress syndrome (ARDS) and multiple-organ failure [8] . Patients presenting with cytokine release syndrome typically show cytopenia, elevated creatinine, deranged coagulation parameters, and high C-reactive protein (CRP) [9] . The common symptoms and cascade of a COVID-19 induced cytokine storm [10] are depicted in Figure 1 . Due to the relationship between cytokine release syndrome and poor outcomes among COVID-19 patients, many of the drugs (small molecules and biologicals) currently being tested aim to dampen this severe immune response, while others target the virus' ability to infect cells. Inflammation resulting from cytokine release starts locally, in areas such as pulmonary tissue, and spreads to other organs through systemic circulation. This triggers compensatory biological repair processes which restore tissue and organ function; however, these processes can lead to fibrosis and persistent organ dysfunction of the lungs, heart, liver and kidney [11] . Many small molecule drugs are metabolized by cytochrome P450 (CYP) enzymes typically expressed in the liver, gut, lung and kidney. Several pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) have been reported to downregulate the expression of these enzymes and transporters such as P-gp by inducing transcription factors (e.g. PXR, CAR, NF-kB, and HNF), which in turn reduce the abundance of CYP450 and P-gp in tissues [12] . This influences the absorption, distribution and metabolism of drugs, as represented in Figure 1 .

Elevated cytokine levels alter the PK, and thus exposure, of small molecules. A few clinical studies have compared drug exposure before and after treatment with cytokines. The use of Interferon (IFN)-α in chronic hepatitis B has been found to decrease theophylline (metabolized mainly by CYP1A2) clearance by 50% and prolong the half-life of the drug by 70% [13] . Alternatively, blocking IL-6 receptor activity with drugs such as sarilumab and tocilizumab reduces the AUC and Cmax of simvastatin (CYP3A4 substrate) by 40-57% [14, 15] .

As clinical studies addressing the impact of different drug metabolizing enzymes and transporters are not always feasible, in vitro models of hepatic and intestinal cell lines can be used. Exposure of hepaRG hepatic cells to IL-6 (10 ng/mL) for 72 h has been found to decrease CYP3A4 mRNA expression and activity by more than 80%, CYP1A2activity by 60%, and CYP2B6 and 2C19 activity by 80% [16] . In EpiIntestinal cells the expression of Phase I enzymes CYP2C19, CYP2C9, and CYP3A4 was reduced by 40-50% (MAO A, 35%; MAO B, 42%), whilst activities of CYP2C19, CYP2C9, and CYP3A4 were suppressed by 20-75% following exposure to IL-6. However, it is worth noting that extrapolation of in vitro results to in vivo models is challenging due to the complexity of biological systems, disease pathophysiology, degrees of severity, changes in cytokines levels, and interactions among cytokines and DME targets [17] .

One added difficulty, for example, is making sure that IL-6is added to cells in concentrations that mimic physiological levels in healthy and diseased states [18] .

Information on Study-sub populations: Remdesivir clinical trial [2] patient characteristics included chronic liver (2%) and kidney disease (6%), cancer (8%) and obesity (37%). 36% of patients were >65 years and patients of different race were included in the trial population.

A large proportion of COVID-19 patients requiring hospitalization and treatment are geriatric [19] and it is likely that this patient population may exhibit exposure differences. The possibility of testing the effect of intrinsic and extrinsic factors clinically is limited, for instance PK on the geriatric COVID-19 patients.

Physiologically-based pharmacokinetic (PBPK) models: The pharmacokinetic; absorption, distribution, metabolism, and excretion (ADME) data for single or multiple doses is relatively abundant for COVID-19 repurposed drugs and can be used to build PBPK models. These models utilize three-components: a system component, a drug-dependent component, and a clinical trial-specific component. Details of human physiology are specified in system components, for instance drug metabolizing enzyme or transporter abundance, tissue blood flow to organs, and so on. Drug properties such as solubility, fraction metabolized by enzymes and renal clearance, are specified in the drug-dependent components, whilst the clinical trialspecific component defines the simulated scenario, including dosing regimen, population age, and gender proportion. PBPK models combine these components to predict drug ADME, and by extension pharmacokinetics (PK), in a simulated scenario where clinical study data are not available. These verified PBPK models can provide the ability to extrapolate beyond the available data and account for disease-drug interactions [20, 21] .

Target site concentrations: As COVID-19 mainly targets lung tissue making it difficult to assess tissue concentration, understanding expected target concentration may be crucial, particularly when attempting to translate observed effect from the in vitro studies to projected clinical situation. PBPK models are useful to predict drug unbound concentrations in the epithelial lining fluid (ELF) [22] which is relevant for treatment of COVID-19 patients, as it can contain a persistent reservoir of the virus.

The objectives of this study were to gather information on the ADME, pharmacokinetic/pharmacodynamic (PK/PD), drug-drug interactions (DDI), adverse events (AEs), and the effect of intrinsic and extrinsic factors on the disposition of all repurposed drugs currently under trial for COVID-19. This enabled us to explore the utility of PBPK models for possible clinical scenarios after verifying them based on the gathered pre-clinical and clinical data. Then we used the models to predict expected alterations in exposure to these drugs in sub-populations of COVID-19 patients which have not yet been studied for some of the drugs e.g., in patients with older age, different race, and hepatic/renal impairment. These variations were studied in relation to target site concentrations.

Trials of drugs repurposed for COVID-19 were selected in this work from the American Society of Health-System Pharmacists (ASHP) list [23] . In addition, two drugs from AstraZeneca currently being studied in clinical trials are acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor [3] , and dapagliflozin, a sodium-glucose transport protein 2 (SGLT2) inhibitor. Details of these and other repurposed drugs are summarized in detail in Table 1 Table 3 ).

For organ dysfunction simulations, AUCdiseased to AUChealthy ratios for both observed and predicted scenarios were calculated as predictive performance measures. The predictability was considered acceptable if this metric fell between the upper and lower limits (0.5 to 2-fold of observed data). Differences in exposure from race in Caucasian, Japanese and Chinese populations were predicted using Simcyp's population library repository using the "Healthy-Volunteer," "Japanese," and "Chinese Healthy Volunteer" population models, respectively.

Simulations for hepatic impairment were performed using Simulator's "Cirrhosis CP-A", "Cirrhosis CP-B", and "Cirrhosis CP-C" populations, while for renal impairment, populations "RenalGFR_30-60", and "RenalGFR_less_30" were used. The effect of age, race and organ impairment simulations were not simulated for baloxavir, remdesivir and large molecules, as adequate PBPK modeling was not possible due to limited data availability in the literature.

Based on recent findings from IQ consortium [24] the impact of renal impairment can be well predicted within 2-fold of observed PK (AUC) and for hepatic impairment >70% of the cases were predicted within 2-fold, supporting the utility of PBPK modeling for the study of organ dysfunction. Physiological differences between healthy volunteers and patients with hepatic organ impairment are shown in Supplementary Table 4 .

The permeability-limited lung model is particularly suitable for modeling and simulating drug disposition within the lung mass compartment and epithelial lining fluid compartment, which are the target sites for anti-viral effects. The methodology of simulating these concentrations has been applied previously to tuberculosis [22] , and recently for three COVID-19 repurposed drugs [25] . In this work, lung epithelial lining fluid concentrations were simulated using geriatric population within PBPK simulator with age range from 65 to 95 years old, with 50% female subjects. The impact of reduced CYP3A expression in the liver and gut by 30% in geriatric population was implemented as shown by Schwenger et al., [20] for oncology subjects to reflect the CYP3A suppression by cytokines.

The predicted Cmax and AUC in healthy subjects were compared to the observed data to ensure the suitability of the models for their intended use. Subsequently, the predicted Cmax and AUC ratios of organ dysfunction (estimated as the ratio of predicted Cmax and AUC of organ dysfunction relative to healthy populations) were compared with the observed organ dysfunction Cmax and AUC ratios. Partition coefficients (KP) between lung tissue and plasma data were available in rats (as shown in Supplementary Table 2) . Rat tissue KP values were compared to in silico predicted human KP values, assuming the unbound distribution is independent of species.

Sensitivity analysis, via Simcyp®'s sensitivity analysis tool, was performed to study the effect of AUC change with reduced CYP3A4 abundance in the liver and gut. Acalabrutinib, ibrutinib, dexamethasone, and darunavir are sensitive CYP3A4 substrates (Table 2) , so these were chosen for these sensitivity analyses. CYP3A4 abundance was varied, with values 10 to 90% lower than those observed in healthy volunteers.

[18] Table 1 shows that in healthy individuals, serum IL-6 concentrations were reported to range from 1.3 to 10.3 pg/ml. They rise to 2.6 to 123 pg/ml in some patient groups with inflammatory diseases including: obesity [26] rheumatoid arthritis [27] , psoriasis [28] , and cirrhosis [29] . A recent meta-analysis reported IL-6 levels in COVID-19 patients with complex clinical complications to be nearly three-fold higher than in patients with few complications [8] . The average serum level of IL-6 across the 6 studies reported in this review was 65.5 pg/ml in patients with SARDS; severe acute respiratory distress syndrome, which is significantly higher than in non-severe cases of disease (21.4 pg/ml) (Table 1) . Mortality rates correlated with higher levels of IL-6, and the addition of IL-6 inhibitors such as tocilizumab improved clinical outcomes with no deaths in a total number of 21 patients receiving treatment [8] . [3] . Table 2 summarizes the observed data of PK/PD properties of repurposed COVID-19 drugs.

The half-maximal inhibitory concentration (IC50) parameters obtained were treated as unbound IC50 because the experimental conditions utilize serum free conditions for COVID-19

drugs and this hypothesis was recently supported by Fan et al [34] . However, the in vivo plasma and lung tissue concentrations were corrected using in silico predicted tissue protein binding and measured plasma protein binding. The preclinical rat partition co-efficient (Kp)

values for lung tissue are compared with human predicted Kp values as listed in Supplementary Table 2 . Figure 2A shows the PBPK model simulated PK profiles for different age brackets: 18 to 40 years, 40 to 65 years, and 65 to 98 years (geriatric population). This age brackets represented a typical demographics from a recent remdesivir clinical trial [2] . We assumed proportion of females in the simulations to be 50%. The PBPK model-based results are in line with observed data as shown in Supplementary Table 3 . Though geriatric population exhibited higher exposure for all drugs compared to the age bracket of 18 to 40 years, but fell within 95% prediction intervals (PI) of healthy volunteers except for dexamethasone, which is marginally outside the shaded area of 95% PI (Figure 2A) . PBPK analysis suggests race has no clinically meaningful effect on the clearance of all COVID-19 drugs, as the mean simulated Chinese and Japanese population profiles fall within 95% PI of Caucasian population ( Figure 2B ) Therefore, no dose adjustment is required based on race of the patient.

Comparing predicted AUCR (AUC0-∞ in hepatic or renal impairment/AUC0-∞ in healthy volunteers) with their corresponding observed values (whenever available) shows consistency within 2-fold of observed data for all drugs, suggesting a developed PBPK models were adequate to simulate the exposure changes where clinical data gap exists. Figure 3A and 3B and Table 4 show how hepatic impairment resulting from cirrhosis and renal impairment (Table 5) , change the exposure levels of these repurposed drugs. The absolute expression of CYP3A levels in mild to severe cirrhotic or renal failure subjects vs Healthy population within Simcyp PBPK Simulator V19 is shown in Supplementary Tables 4 and 5. In addition physiological differences between either liver cirrhosis or renal impairment populations vs Healthy population is also described. The exposure of azithromycin, atazanavir, acalabrutinib, ruxolitinib, and dexamethasone was clearly higher in severe hepatic impairment ( Figure 3A ) relative to healthy volunteers, suggesting the need for dose adjustment. In case of renal impairment ( Figure 3B) , ruxolitinib, atazanavir and azithromycin plasma exposures were higher in severe conditions relative to healthy population and may warrant a dose adjustment in severe renally impaired patients. range of target inhibition The input parameters used for the permeability-limited lung model [22] al., [89] and shown in Supplementary Table 2 . This lysosomotropic potential of chloroquine, hydroxychloroquine, atazanavir and remdesivir were appeared to be beneficial for attaining a required target exposure and efficacy. However increased exposure might also have consequences towards side effects.

The relative change in exposure (AUC) for CYP3A substrates such as acalabrutinib and ibrutinib when CYP3A expression reduced to one tenth of its healthy level in both the gut and liver is shown in Figure 5 . As a worst-case scenario, reducing 90% of CYP3A4 abundance in liver and gut, resulted in ~4-fold increase in AUC for acalabrutinib and dexamethasone, while In many instances no clinical DDI data are available as exemplified by the combination of ritonavir (a CYP3A reversible and time dependent inhibitor) with BTK inhibitors such as ibrutinib and acalabrutinib. Based on PBPK modeling, the DDI risk appears to be higher with ibrutinib when combined with ritonavir (AUC ratio of ~44-fold), while ritonavir combination increased acalabrutinib AUC by 5.7-fold); however, no DDI risk is anticipated for dapagliflozin as it is mainly eliminated by UGT1A9 substrate.

As many of the repurposed drugs studied in this paper are primarily metabolized in the liver, it was unsurprising to find that impaired liver function or liver disease impacts the PK of these drugs. Baricitinib is mainly excreted unchanged by the kidney and thus its PK can be altered in renal failure conditions. PBPK models suggest dosing adjustments for CYP3A4 substrates like ibrutinib, dexamethasone, and acalabrutinib are likely to be necessary. PBPK ensures more appropriate use of tissue site concentrations compared to populationbased PK modeling, and allows us to account for disease-drug interaction i.e. cytokine storm.

In this study, we utilize in vitro IC50 rather than in vivo EC50 due to scarcity of this data.

Nevertheless, when unbound in vivo EC50 data becomes available, one can easily update the exposure profiles with the relevant target inhibition values and explore IVIVE, as shown in Pilla Reddy et al., [96] In vitro IC50 were generated for anti-viral drugs using serum free media in most instances, and thus we can assume in vitro IC50 are basically unbound values; however, in-vivo lung tissue and plasma profiles should be corrected for lung tissue protein binding and plasma protein binding respectively to obtain KP,uu, under the assumption that the unbound drug is pharmacologically active [34] .

Simulating the plasma and/or lung exposure of drugs used to treat COVID-19 is important, as the unbound tissue concentration drives the efficacy and safety of a drug. Non-invasive imaging methods (PET/MRI) can be used to determine tissue drug concentrations; however, it is logistically challenging to routinely employ these methods during drug development. We therefore need high-throughput and cost-efficient methods to predict the tissue concentration of drugs. To achieve this, we must accurately predict drug distribution and clearance into and out of tissue. We hypothesize that lung concentrations of drugs can be predicted through in vitro to in vivo extrapolation by incorporating the appropriate parameters such as permeability and transporter data. Preclinical, quantitative, whole-body autoradiography distribution data could be used to understand the partition between plasma and lung tissue or organ of interest to some extent, assuming the unbound partition coefficient is independent of species. Quantitative whole-body autoradiography data in rats was available for most of the drugs, facilitating comparisons with predicted total KP values within the Simcyp Simulator.

The prediction of ELF unbound concentration is particularly relevant for COVID-19 patients, as the distribution of COVID-19 drugs should be targeted into immune privileged sites like ELF in the lung which may represent a persistent reservoir for the virus [11] . Highly ionizable drugs might experience different lung uptake due to changes in lung pH resulting from COVID-19;

this was accounted for in our PBPK model. One limitation of this work is that ELF concentrations were simulated using geriatric populations with reduced CYP expression in the liver and gut by 30% which was optimized based on cancer patients [20] . The PK differences between healthy volunteer vs COVID-19 for given drug yet to be established.

In summary, in this study we provide a database for relevant PK, PD 

The authors would like to thank the patients, their families, and the clinical teams who worked on the studies.

Venkatesh 

Eman is supported by PhD funding from the Egyptian government and CAPKR. Venkatesh Pilla In Figure 2A , the black continuous line represents the median prediction using the PBPK model for 18-40yrs of age; green line for 40 to 65 years and red line for 65 to 98 years of age. The shaded area represents the 95% prediction intervals of Caucasian healthy volunteers. In Figure 2B , the black continuous line represents the median prediction using the PBPK model for Caucasians subjects. green line is for Japanese subjects and red line for Chinese patients. All these effect of Race simulations were run using 40 to 65 years of age with 50% of females. 

The black continuous line represents the median prediction using the PBPK model for healthy population. The shaded area represents the 95% prediction intervals of healthy population. Blue line represents mild hepatic impairment. Green line represents moderate renal or hepatic impairment; red line represents severe renal or hepatic impairment.

Doses used for hepatic impairment: Acalabrutinib 50 mg single dose, azithromycin 500mg  single dose, atazanavir 400mg single dose, chloroquine 300mg single dose, dapagliflozin 10mg  single dose, hydroxychloroquine base (HCQ) 155 mg single dose, baricitinib 4mg single dose,  ritonavir 600mg single dose, ruxolitinib 25mg single dose, lopinavir 400 mg single dosing  interval (with 100mg ritonavir This article is protected by copyright. All rights reserved. 

Enhancing the Diversity of Clinical Trial Populations -Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency

Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis

A Review of Coronavirus Disease-2019 (COVID-19)

The pathogenesis and treatment of theCytokine Storm'in COVID-19

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

Inhibition of theophylline metabolism by interferon

Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis

Coordinating Role of RXRalpha in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic Modeling

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

Drug-Cytokine Interactions

Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting-a cohort study

Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

Impact of disease on plasma and lung exposure of chloroquine, hydroxy-chloroquine and azithromycin: application of PBPK modelling

Raised interleukin-6 levels in obese patients

Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection

Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture

IL-6) and Hepatocyte Growth Factor in Patients with Alcoholic Liver Cirrhosis

The Correlation between Increased Serum Concentrations of Interleukin-6

Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Azithromycin induces anti-viral responses in bronchial epithelial cells

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial

HIGHLIGHTS OF PRESCRIBING INFORMATION: XOFLUZATM (baloxavir marboxil) tablets, for oral use

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

An image analysis algorithm for malaria parasite stage classification and viability quantification

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

HIV protease inhibitors: a review of molecular selectivity and toxicity

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis

Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats

Dose-dependent pharmacokinetics of dexamethasone

<Tocilizumab FDA label.pdf>

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis

Interferon-beta 1a and SARS coronavirus replication

Acalabrutinib FDA NDA.. Highlights of prescribing information for Calquence (acalabrutinib) capsules, for oral use

Highlights of prescribing information for Zithromax (azithromycin) for IV infusion only

Highlights of prescribing information: Olumiant (baricitinib) tablets, for oral use

Highlights of Prescribing Information: Xofluza (baloxavir marboxil)

Hydroxychloroquine sulfate tablets, USP. In, 2019. 65. Darunavir, FDA NDA

Highlights of prescribing information for FARXIGA (dapagliflozin)

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

Remdesivir FDA Label,. Fact sheet for health care providers: Emergency use authorization (EUA) of Remdesivir (GS-5734)

Highlights of prescribing information for JAKAFI (ruxolitinib) tablets, for oral use

Highlights of prescribing information for NORVIR (ritonavir) tablet, for oral use/ oral solution/ oral powder

NDA/BLA Multi-disciplinary Review and Evaluation {NDA 210259} {CALQUENCE, acalabrutinib}

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>

Pharmacokinetics of azithromycin in patients with impaired hepatic function

Disposition of chloroquine in man after single intravenous and oral doses

Bioavailability of hydroxychloroquine tablets in healthy volunteers

NDA/BLA Multi-disciplinary Review and Evaluation {NDA 20792} {Baricitinib}. This article is protected by copyright. All rights reserved

Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C viruscoinfected subjects with hepatic impairment

Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment

Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients

Highlights of prescribing information for Dexamethsone (Hemady)

Pharmacokinetics of azithromycin in normal and impaired renal function

Pharmacokinetics of chloroquine in renal insufficiency

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages

Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations

Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation

The modulating effects of endogenous substances on drug metabolising enzymes and implications for inter-individual variability and quantitative prediction

The pharmacokinetic-pharmacodynamic (PKPD) relationships of AZD3229, a novel and selective inhibitor of cKIT, in a range of mouse xenograft models of GIST

Dose reduction to 300 mg per day is recommended in moderate HI

No significant change in dose for moderate cirrhosis. Not studied in severe HI

Ruxolitinib 25 mg SD CP-A:1.87 (90%CI 1.29-2.71) CP-B

19) Reduce dose is recommended in patients with any HI

Ritonavir 600 mg SD

No dose adjustment of ritonavir is necessary for patients with either mild or moderate HI. No pharmacokinetic or safety data are available regarding the use of ritonavir in subjects with CP-C, therefore, ritonavir is not recommended for use in patients with severe HI

Remdesivir Day 1: SD 200 mg IV N/A N/A N/A The pharmacokinetics and dosage adjustment of remdesivir have not been evaluated in patients with HI

All authors were involved in designing the studies and performing the study analyses. All authors wrote the manuscript. VPR, EE, and HJ performed the modeling analyses. All authors have approved the manuscript for submission.

The authors confirm that the clinical data supporting the PBPK modeling are listed in clinicaltrial.gov and details of these clinical studies published elsewhere. The data that support the findings of this study are available from supplementary files and repository of PBPK files can be found in Simcyp members area This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved. Bronchitis, diarrhea, nausea, nasopharyngitis and headache [62] This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. No dose adjustment is recommended for patients with mild, moderate, or severe HI. However, the benefit-risk for the use of dapagliflozin in patients with severe HI should be individually assessed since the safety and efficacy of dapagliflozin have not been specifically studied in this population. [66] This article is protected by copyright. All rights reserved. The change in exposure in mild and moderate HI is not expected to be clinically relevant. Lopinavir has not been studied in patients with severe hepatic impairment.This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. N/A Ritonavir pharmacokinetics have not been studied in patients with renal impairment, however, since renal clearance is negligible, a decrease in total body clearance is not expected in patients with renal impairment [71] This article is protected by copyright. All rights reserved.